<DOC>
	<DOCNO>NCT01930058</DOCNO>
	<brief_summary>This adaptive design study evaluate safety , pharmacokinetics , effect hepatitis C virus ( HCV ) RNA level multiple dos MK-8876 participant HCV infection . The study consist 4 part evaluate participant infect specific hepatitis C virus genotypes 10 panel allow additional participant enroll panel specify study analysis . The hypothesis evaluate study ≥2.5 log IU/mL reduction HCV RNA Baseline accompany multiple dose administration MK-8876 participant HCV infection .</brief_summary>
	<brief_title>Safety , Pharmacokinetics , Pharmacodynamics MK-8876 Participants With Hepatitis C Infection ( MK-8876-003 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>male , female nonchildbearing potential ( nonchildbearing potential define postmenopausal without menses ≥1 year medically document hysterectomy , oophorectomy , tubal ligation ) agree use medically acceptable method contraception 90 day last dose study drug participant female partner childbearing potential must ( male use condom partner childbearing potential must use hormonal contraception , intrauterine device , diaphragm , cervical cap , female condom ) body mass index ( BMI ) 18 37 kg/m^2 clinical diagnosis chronic HCV infection define positive serology HCV ≥6 month agree follow smoke trial restriction mentally legally institutionalize incapacitate , significant emotional problem study start clinically significant psychiatric disorder last 5 year history clinically significant endocrine , gastrointestinal ( except HCV infection ) , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases history stroke , chronic seizure , major neurological disorder history cancer ( except adequately treat nonmelanomatous skin carcinoma , carcinoma situ cervix , malignancy successfully treat ≥10 year history significant multiple and/or severe allergy anaphylactic reaction significant intolerability drug food history clinically significant hepatic disease , Gilbert 's disease , biliary tract disease , human immunodeficiency virus major surgery donate lose &gt; 1 unit blood within 4 week study participate another investigational trial within 4 week study Is unable refrain anticipates use medication 2 week study throughout study consumes &gt; 2 glass alcoholic beverage per day consumes &gt; 6 serving ( 1 serve ~120 mg caffeine ) coffee , tea , cola , energy drink , caffeinated beverage per day regular user illicit drug history drug abuse within 12 month study evidence history chronic hepatitis cause HCV ( except acute nonHCVrelated hepatitis resolve &gt; 6 month study ) previously receive treatment another HCV nonnucleoside inhibitor ( previous use HCV investigational therapy market compound permitted treatment end ≥3 month study ) clinical laboratory evidence advance decompensated liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>